Respiratory Syncytial Virus (RSV) is a single-stranded RNA virus that primarily infects the respiratory tract, causing a range of respiratory illnesses. It is a significant global health concern, affecting individuals of all ages. While RSV infections are most severe in infants and young children, they can also lead to substantial morbidity and mortality in older adults and individuals with underlying health conditions. The virus enters the body through the eyes, nose, or mouth and typically manifests as cold-like symptoms, progressing to more severe respiratory distress in vulnerable populations. RSV is responsible for a substantial burden of hospitalizations, particularly during peak seasons. The impact extends beyond acute illness, as studies have shown associations between RSV infection in early childhood and the development of respiratory issues later in life. Efforts to combat RSV involve ongoing research into antiviral medications and vaccine development. However, challenges in creating a universally effective vaccine persist due to the virus's ability to mutate. Preventive measures, such as maintaining good hand hygiene, promoting vaccination where available, and implementing infection control practices in healthcare settings, are crucial for reducing RSV transmission. Given the dynamic nature of RSV and its potential long-term implications, a comprehensive approach that combines public health interventions, medical research, and community education is essential to effectively manage and mitigate the impact of this respiratory virus.